Two Sigma Securities’s Immunovant IMVT Stock Holding History

Two Sigma Securities’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,281	Closed	-$279K	–	1738
2025 Q3	$279K	Buy	+17,281	New	+$280K	0.04%	622

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Two Sigma Securities's IMVT Position: Q4 2025 in Review

Two Sigma Securities sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 17,281 shares — an estimated $279K sold.

Two Sigma Securities first reported a position in IMVT in Q3 2025 and held it in 1 quarter. The position peaked at $279K in Q3 2025. 196 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

Two Sigma Securities reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
Two Sigma Securities sold 17,281 Immunovant shares in Q4 2025, an estimated $279K.
Two Sigma Securities first reported a position in Immunovant in Q3 2025 and held it in 1 quarter.
Two Sigma Securities's Immunovant position peaked at $279K in Q3 2025.
196 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.